Nifedipine (Addos XR): Patient Guide For Australia

Basic Addos XR Information

• INN (International Nonproprietary Name): Nifedipine
• Brand Names Available In Australia: Adalat, Adalat CC, Procardia XL, Nifediac, Nifedical, Afeditab CR (global brands listed in product information; local availability varies)
• ATC Code: C08CA05 — C08: Calcium Channel Blockers; C08CA: Dihydropyridine Derivatives; C08CA05: Nifedipine
• Forms & Dosages: Extended-Release Tablets 30 mg / 60 mg / 90 mg; Immediate-Release Capsules 10 mg / 20 mg; Modified-Release Tablets 20 mg / 30 mg / 60 mg
• Manufacturers In Australia: Not Specified (global suppliers include Bayer, Teva, Sandoz/Novartis, Mylan, Actavis, Apotex; local sponsors vary)
• Registration Status In Australia: Not Specified (product registration and ARTG sponsor details vary by brand and should be checked on the TGA ARTG)
• OTC / Rx Classification: Prescription-Only Medicine (Rx) — generally required worldwide

Latest Research Highlights Australia + Global

Nifedipine is a dihydropyridine calcium channel blocker used for hypertension and angina, with extended-release formulations commonly preferred for chronic therapy.

Extended-release preparations aim to provide once-daily blood-pressure control and reduce peaks and troughs associated with immediate-release forms.

Immediate-release nifedipine has historically been associated with rapid falls in blood pressure and reflex tachycardia, which is why ER formulations are favoured for outpatient management.

Common adverse effects reported with dihydropyridine calcium channel blockers include peripheral oedema, flushing and headache, often dose related.

Combination therapy with ACE inhibitors, ARBs or thiazide diuretics is widely used to achieve target blood-pressure goals while attempting to limit dose-related side effects such as oedema.

Regulatory advice and safety notes emphasise careful titration in elderly patients and those with hepatic impairment due to hepatic metabolism of nifedipine.

Clinical Effectiveness In Australia

Nifedipine ER is used in Australia for sustained antihypertensive therapy and chronic stable angina as part of standard treatment options.

Typical ER dosing commonly starts at 30 mg once daily with maintenance usually between 60 mg and 90 mg once daily depending on response and tolerability.

Prescribers often choose extended-release formulations to reduce night-time blood-pressure variability and to simplify once-daily dosing for adherence.

When used within guideline-recommended regimens and combined with ACE inhibitors or thiazide-type diuretics, nifedipine ER contributes to comparable cardiovascular outcome markers.

Pharmacovigilance guidance supports slower titration in elderly patients and those with impaired hepatic function because nifedipine is predominantly metabolised in the liver.

Data Highlights: PBS listing status and ARTG sponsor details influence the brand patients receive and patient co-payment amounts.

Indications And Expanded Uses TGA Vs Off-Label

Approved indications align with international practice: hypertension and angina pectoris, including stable and vasospastic angina.

Off-label specialist uses reported in some settings include paediatric hypertension in specialised care (for example post-transplant) and Raynaud-type vasospasm under specialist supervision.

Immediate-release nifedipine is sometimes used in-hospital but is generally avoided for ambulatory rapid blood-pressure lowering because of safety concerns.

In primary care, clinicians may select ER nifedipine for chronic control and use alternatives such as amlodipine when patients experience troublesome side effects.

Composition And Brand Landscape Addos XR Focus

The active ingredient is nifedipine (INN), ATC code C08CA05, a dihydropyridine calcium channel blocker indicated for hypertension and angina.

Addos XR is one of several extended-release nifedipine brands; other well-known trade names include Adalat and Procardia XL internationally.

Common ER tablet strengths available globally are 30 mg, 60 mg and 90 mg, with packaging often in 28–30 tablet blister packs.

Original manufacturer historically is Bayer AG, and multiple generics are manufactured by Teva, Sandoz/Novartis, Mylan, Actavis and Apotex.

In Australia, brand availability and PBS subsidy depend on ARTG sponsor entries and PBS schedule listings, so brand and price can vary between pharmacies and states.

Contraindications And Special Precautions Australian Focus

Absolute contraindications include known hypersensitivity to nifedipine or excipients, severe coronary artery disease, recent myocardial infarction within two weeks, cardiogenic shock and severe aortic stenosis.

Concurrent rifampin use is contraindicated because it markedly reduces nifedipine exposure.

Relative contraindications requiring careful monitoring include impaired hepatic function, severe hypotension, congestive heart failure, significant gastrointestinal surgery, diabetes and hypothyroidism.

Elderly patients require slower titration and closer observation for orthostatic hypotension and dizziness.

Pregnancy and breastfeeding situations should be assessed by a specialist; nifedipine may be used in some obstetric settings under specialist supervision.

• Absolute Contraindications: Hypersensitivity; severe CAD; recent ≤2-week MI; cardiogenic shock; severe aortic stenosis; rifampin coadministration.
• Relative Contraindications: Hepatic impairment; severe hypotension; CHF; GI surgery; diabetes; hypothyroidism; elderly patients.

Dosage Guidelines Australia-Relevant

For hypertension and chronic stable angina, the usual starting dose is a 30 mg ER tablet once daily.

Maintenance dosing is commonly 60–90 mg once daily, with a typical maximum of 90 mg ER per day.

Immediate-release preparations (10–20 mg) exist but are generally not preferred for outpatient rapid blood-pressure lowering.

Children require specialist, weight-based dosing and are treated only in specialist settings for selected indications such as post-transplant hypertension.

Elderly patients should start at lower doses with slow titration, and hepatic impairment mandates dose reduction and monitoring of liver function.

When stopping nifedipine, avoid abrupt cessation to reduce the risk of rebound hypertension or worsening angina; taper under clinician guidance.

Interactions Overview Food Drugs Supplements

Nifedipine is metabolised by hepatic CYP3A4 enzymes, so strong CYP3A4 inducers such as rifampin reduce nifedipine exposure and are contraindicated.

CYP3A4 inhibitors including some macrolide antibiotics and antifungals can increase nifedipine levels and worsen hypotension; monitor closely if coadministration is unavoidable.

Grapefruit juice increases nifedipine exposure and should be avoided while taking nifedipine.

Alcohol can potentiate vasodilatory and orthostatic effects; advise moderation.

Concurrent antihypertensives (ACE inhibitors, ARBs, diuretics, beta blockers) increase the risk of hypotension but are commonly used together with monitoring.

Cultural Perceptions And Patient Habits In Australia

Australian patients tend to be cost-conscious and rely heavily on pharmacists for medicine advice and PBS subsidy information.

Once-daily ER formulations are appreciated for convenience, and pharmacy chains and independent pharmacies are common access points.

Rural and remote patients use telehealth and local health services for continuity, but monitoring such as BP checks may be spaced out compared with urban care.

Indigenous health services emphasise culturally safe counselling and tailored follow-up when initiating antihypertensives in communities with higher rates of diabetes and renal disease.

• Urban Persona: Values convenience and brand advice from pharmacist in-store.
• Rural Persona: Prefers telehealth follow-up and local pharmacy dispensing; may experience occasional stock substitutions.
• Indigenous Communities: Require culturally appropriate counselling and clear monitoring plans.
• Cost-Sensitive Patients: Seek PBS-subsidised generics or chain prices.

Availability And Pricing Patterns Retail And PBS

Availability in Australia depends on TGA ARTG entries and PBS subsidy listings for specific brands and formulations.

Major retail channels include Chemist Warehouse, Priceline and TerryWhite Chemmart, plus independent pharmacies and accredited online pharmacies that accept e-prescriptions.

PBS-listed formulations attract patient co-payment subsidies, while private prescriptions and non-PBS brands incur the full retail cost.

Online sales and telehealth scripts can increase access, but ensure prescriptions are legitimate and ARTG/brand details are confirmed with the dispensing pharmacist.

In our online pharmacy, addos xr is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences Pros Cons

Alternatives commonly considered in Australia include amlodipine, felodipine and nicardipine (nicardipine often used intravenously in acute care).

Amlodipine has a longer half-life and a gentler onset which may reduce reflex tachycardia and be easier to titrate in elderly patients.

Pros of nifedipine ER include potent vasodilation and established use for hypertension and angina when dosed correctly.

Cons include a higher incidence of peripheral oedema and flushing compared with some alternatives, and the need for hepatic metabolism caution with interacting drugs.

Frequently Asked Questions

Q: Can I stop Addos XR suddenly?

A: No. Abrupt cessation can worsen angina or cause rebound hypertension; taper under clinician guidance.

Q: Will nifedipine make me swell?

A: Peripheral oedema is a common side effect; lowering dose or combining with an ACE inhibitor or diuretic can help and should be discussed with your prescriber.

Q: Is grapefruit juice a problem?

A: Yes. Avoid grapefruit and pomelo while taking nifedipine as they increase drug exposure and hypotension risk.

Q: Can I get Addos XR on the PBS?

A: Availability and subsidy depend on ARTG listing and the PBS schedule for the specific brand; check with your GP or pharmacist for current status.

Guidelines For Proper Use And Pharmacist Counselling

Confirm the indication and review current medications for CYP3A4 inhibitors or inducers before dispensing nifedipine.

Advise patients that the usual starting dose is 30 mg ER once daily and that benefits may be seen within days but full BP control may take longer.

Warn about dizziness and orthostatic hypotension, particularly during initiation or dose increases, and instruct patients not to drive until they know how the medicine affects them.

Emphasise adherence: do not double up missed doses and avoid abrupt stopping; tapering should be managed by the prescriber.

For remote or Indigenous patients, set clear telehealth BP check schedules and coordinate with local health services for timely monitoring of BP and liver function as needed.

• Counselling Checklist: Indication, dose, missed-dose rules, side effects, interactions (grapefruit, rifampin), monitoring plan.
• Patient Handout Template: Name, dose, when to take, warnings about grapefruit/alcohol, emergency signs to seek care for.

Delivery Across Australia